This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||
|
The following Wikipedia contributor may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include
conflict of interest and
neutral point of view.
|
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Duvelisib.
|
I haven't seen a table of patent info in other drug articles, so I'm wondering if it adds relevant info to the article here. It's an article about an experimental drug, so I can see the argument for including it because the topic is different than that of marketed drugs, but I'd like other opinions. Natureium ( talk) 15:19, 19 January 2017 (UTC)
Robert Forrester, CEO of Verastem, answered some questions about the way Duvelisib ended up at Verastem in the Nov 14, 2017 in the Q&A after his presentation at the Jefferies healthcare conference, and there is more to it than is explained in the wikipedia article. Some of it is hard to make out on the webcast, but it sounds extremely interesting. (Anyone can see the webcast, but this sort of presentation tends to disappear from the webcast after some small number of months.) 108.45.80.41 ( talk) 08:47, 18 November 2017 (UTC)
This drug was considered as 'failed' by infinity, as NHL results in the duo study were not as planned. (There is a on almost emotional PR from Infinity on this). The CLL trial was ongoing, and the compound sold to Verastem, for little money. This year, the CLL trial had been found to be successful. Wowbagger2 ( talk) 14:46, 27 December 2017 (UTC)
This edit request by an editor with a conflict of interest was declined. Please see the Reply section below for additional information about your request. |
Duvelisib, sold under the trade name Copiktra™, is a medication approved to treat a number of different forms of blood cancers. Citation: FDA https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm— Preceding unsigned comment added by 136.24.42.57 ( talk) 20:55, 18 October 2018 (UTC)
Unable to review edit request
Your edit request could not be reviewed because the request is not formatted correctly.
In the collapsed section below titled Request edit examples, I have illustrated two: The first shows how the edit request was submitted; the second shows how requests should be submitted in the future.
Request edit examples
|
---|
In the example above there are three URL's provided with the claim statements, but these URL's have not been placed using Citation Style 1, which is the style predominantly used by the Duvelisib article. Additionally, the references have not been placed within the text at the exact positions where the information they reference resides. Using the correct style and the correct positioning of the ref notes, the WikiFormatted text would resemble the following:
In the example above the references have been formatted according to Citation Style 1, which shows the author, the source's name, date, etc. Also, the reference notes are placed in the exact location where the text which they reference resides. As Wikipedia is a volunteer project, edit requests such yours are generally expected to have this formatting done before the request is submitted for review. |
Kindly rewrite your edit request so that it aligns more with the second example shown in the collapsed section above, and feel free to re-submit that edit request at your earliest convenience. If you have any questions about this formatting please don't hesitate to ask myself or another editor. Regards, Spintendo 04:52, 11 October 2018 (UTC)
Notes
This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||
|
The following Wikipedia contributor may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include
conflict of interest and
neutral point of view.
|
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Duvelisib.
|
I haven't seen a table of patent info in other drug articles, so I'm wondering if it adds relevant info to the article here. It's an article about an experimental drug, so I can see the argument for including it because the topic is different than that of marketed drugs, but I'd like other opinions. Natureium ( talk) 15:19, 19 January 2017 (UTC)
Robert Forrester, CEO of Verastem, answered some questions about the way Duvelisib ended up at Verastem in the Nov 14, 2017 in the Q&A after his presentation at the Jefferies healthcare conference, and there is more to it than is explained in the wikipedia article. Some of it is hard to make out on the webcast, but it sounds extremely interesting. (Anyone can see the webcast, but this sort of presentation tends to disappear from the webcast after some small number of months.) 108.45.80.41 ( talk) 08:47, 18 November 2017 (UTC)
This drug was considered as 'failed' by infinity, as NHL results in the duo study were not as planned. (There is a on almost emotional PR from Infinity on this). The CLL trial was ongoing, and the compound sold to Verastem, for little money. This year, the CLL trial had been found to be successful. Wowbagger2 ( talk) 14:46, 27 December 2017 (UTC)
This edit request by an editor with a conflict of interest was declined. Please see the Reply section below for additional information about your request. |
Duvelisib, sold under the trade name Copiktra™, is a medication approved to treat a number of different forms of blood cancers. Citation: FDA https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm— Preceding unsigned comment added by 136.24.42.57 ( talk) 20:55, 18 October 2018 (UTC)
Unable to review edit request
Your edit request could not be reviewed because the request is not formatted correctly.
In the collapsed section below titled Request edit examples, I have illustrated two: The first shows how the edit request was submitted; the second shows how requests should be submitted in the future.
Request edit examples
|
---|
In the example above there are three URL's provided with the claim statements, but these URL's have not been placed using Citation Style 1, which is the style predominantly used by the Duvelisib article. Additionally, the references have not been placed within the text at the exact positions where the information they reference resides. Using the correct style and the correct positioning of the ref notes, the WikiFormatted text would resemble the following:
In the example above the references have been formatted according to Citation Style 1, which shows the author, the source's name, date, etc. Also, the reference notes are placed in the exact location where the text which they reference resides. As Wikipedia is a volunteer project, edit requests such yours are generally expected to have this formatting done before the request is submitted for review. |
Kindly rewrite your edit request so that it aligns more with the second example shown in the collapsed section above, and feel free to re-submit that edit request at your earliest convenience. If you have any questions about this formatting please don't hesitate to ask myself or another editor. Regards, Spintendo 04:52, 11 October 2018 (UTC)
Notes